Boan Boston

Boan Biotech is a fully integrated biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic antibodies. A subsidiary of Luye Pharma Group, the company operates R&D centers in Yantai, China, and Boston, USA, focusing on oncology, metabolism, autoimmunity, and ophthalmology. Boan Biotech possesses a comprehensive portfolio that includes marketed biosimilars such as Boyounuo (bevacizumab) and Boyoubei (denosumab), alongside a robust pipeline of innovative biologics, bispecific antibodies, and antibody-drug conjugates (ADCs). The company leverages its proprietary platforms, including the BA-huMab human antibody transgenic mouse technology, to accelerate the discovery of high-affinity therapeutic candidates for global markets.